India to South Africa: Cytarabine Export Trade Route

The India to South Africa Cytarabine corridor is one of India's established pharmaceutical export routes, with 26 shipments documented worth a combined $489.1K USD. The route is dominated by FRESENIUS KABI ONCOLOGY LIMITED, which alone accounts for roughly 96% of all export value, reflecting the consolidated nature of India's cytarabine manufacturing sector.

Across 4 active suppliers, the average shipment value stands at $18.8K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (69%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during October–December, with an average transit time of 29 days port-to-port. The route has recorded an annual growth rate of 33.7%, placing it at rank #2 among India's top cytarabine export destinations globally.

On the import side, key buyers of Indian cytarabine in South Africa include FRESENIUS KABI SOUTH AFRICA PTY LT, FRESENIUS KABI SOUTH AFRICA (PTY) L, FRESENIUS KABI SOUTH AFRICA PTY L and 8 others. FRESENIUS KABI SOUTH AFRICA PTY LT is the single largest importer with 2 shipments valued at $217.9K USD.

India's cytarabine exports to South Africa are driven primarily by a handful of large-scale manufacturers. FRESENIUS KABI ONCOLOGY LIMITED with 8 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 4 active exporters signals a competitive but concentrated market — buyers in South Africa benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — FRESENIUS KABI ONCOLOGY LIMITED, JPC GLOBAL, VAMA LIFECARE PRIVATE LIMITED — together account for 100% of total trade value on this route. The average shipment value of $18.8K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as cytarabine cytarabine fresenius inj 500mg 5ml vial batch no 87250088ba mfg dt 03 2025 exp dt 08 2026 and cytarabine fresenius inj. 500mg/5ml vialbatch no. 87240193ba, mfg. dt. 05/2024, exp. dt. 10/2025, suggesting that buyers in South Africa tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, FRESENIUS KABI SOUTH AFRICA PTY LT is the largest importer with 2 shipments worth $217.9K USD — representing 45% of all cytarabine imports from India on this route. A total of 11 buyers are active on this corridor.